Author Topic: Glennon's Drug Discrimination Studies  (Read 3027 times)

0 Members and 1 Guest are viewing this topic.

Rhodium

  • Guest
Glennon's Drug Discrimination Studies
« on: August 18, 2003, 05:01:00 PM »
Arylalkylamine Drugs of Abuse: An Overview of Drug Discrimination Studies
Richard A. Glennon

Pharmacology Biochemistry and Behavior, Vol. 64, No. 2, pp. 251–256 (1999)

(https://www.thevespiary.org/rhodium/Rhodium/pdf/glennon.arylalkylamine.drugs.of.abuse.pdf)
DOI:

10.1016/S0091-3057(99)00045-3





Abstract

Abused arylalkylamines fall into two major categories: the indolealkylamines, and the phenylalkylamines: These agents can be further subclassified on the basis of chemical structure. Examples of these agents possess hallucinogenic, stimulant, and other actions. Drug-discrimination techniques have been used to classify and investigate this large family of agents. Such studies have allowed the formulation of structure–activity relationships and investigations of mechanisms of action. Arylalkylamine designer drugs also possess the same or a combination of actions, and are being investigated by the same methods.